Mollie Barnes

Freelance writer

Mollie Barnes is a freelance science writer. Reach her at mollie@100yearsco.com. Follow her on Threads and Instagram @shejustlikedtogo or LinkedIn. See more of her work at molliebarnes.contently.com.

Pictured: A red, blue and purple racecar zip aroun

Drug Development

Mirati, Amgen, Lilly and More Race to the Front Line in KRAS-Mutated NSCLC

While Amgen and Mirati are widely viewed as frontrunners to win the first front line approval, analysts—and competitors—say the field is still wide open.

November 21, 2023

6 min read

Mollie Barnes

Illustration of a computer choosing from a display

Career Advice

How Companies Use AI to Grade Candidates—and Even Potential Locations

The biopharma industry is moving toward using AI to try to determine how well a given person would perform in a role, with applications that go beyond recruiting.

November 1, 2023

5 min read

Mollie Barnes

A 3D rendering of a messenger RNA strand/iStock, l

Drug Development

First RNA Editing Therapy Nears Clinic as Excitement Mounts

Its reversible nature offers the potential for RNA editing to go beyond rare diseases, eliciting excitement and buy-in from large pharmas like GSK and Eli Lilly.

October 4, 2023

5 min read

Mollie Barnes

A cartoon depicting one person with a large pile o

Deals

How Some Companies Are Winning in a Parched Funding Climate

Here’s how some biopharmas have managed to gain funding despite a falloff in investment in the sector. Hint: Positive late-stage data is a key factor.

October 3, 2023

4 min read

Mollie Barnes

Pictured: An entrance to Purdue University campus/

Feeder Programs First Step in Bringing More Diversity to Pharma

Purdue University and Eli Lilly begin one of the only scholarship programs in the country aimed at seniors in high school, while other companies launch similar initiatives for graduate students.

September 5, 2023

5 min read

Mollie Barnes

External view of the U.S. Capitol building at sunset

Policy

Amid IRA Legal Battle, House Democrats Push to Expand Its Scope

As biopharma companies look to prove price setting provisions in the Inflation Reduction Act are unconstitutional, lawmakers unveil legislation to further reduce drug costs.

August 8, 2023

4 min read

Mollie Barnes